- Raised $50M funding round, Feb 2021
- Raised $6M funding round, Aug 2018
- Raised $2.7M funding round, Sep 2020
About
Novaremed, a privately held clinical-stage biopharmaceutical company, is developing effective and safe treatment options for managing chronic pain as an alternative to opioids. The company's lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, FDA Fast Track Designation, and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy. The earlier stage pipeline addressing chronic pain includes candidates MP-101 (Phase 2 stage), targeting prevention and treatment of chemotherapy-induced peripheral neuropathy; and MP-103 (preclinical stage). Novaremed's clinical development portfolio aims to satisfy high medical patient needs and societal demands by alleviating the burden of pain associated with diabetes and cancer for patients and countering over-reliance on addictive treatments. Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland).
Funding history · 6 rounds · $67.2M total
Q&A
- What is Novaremed's primary focus?
- Novaremed is a clinical-stage biopharmaceutical company focused on developing effective and safe non-opioid treatment options for managing chronic neuropathic pain.
- What is Novaremed's lead product?
- Novaremed's lead product is NRD.E1, an orally active non-opioid small molecule with FDA Fast Track Designation, which is approved for a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy.
- When was Novaremed founded?
- Novaremed was founded in September 2008.
- What is Novaremed's total funding to date?
- Novaremed has raised a total of $67,159,176 USD across multiple funding rounds.
- When was Novaremed's most recent funding round and who participated?
- Novaremed's most recent funding round occurred in February 2021, with participation from GEM Global Yield LLC.
- Where is Novaremed headquartered?
- Novaremed is headquartered in Petah Tikva, Israel, with an additional office in Basel, Switzerland.
- Who is the Founder and CEO of Novaremed?
- Eliahu Kaplan, M.D. is the Founder and CEO of Novaremed.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | novaremed.com |
|---|---|
| linkedin.com/company/28642608 | |
| Wikidata | wikidata.org/wiki/Q140045388 |
Identifiers & details
| Founded | 2008-9 |
|---|---|
| Employees (exact) | 10 |
| Offices | Basel |
| Wikidata QID | Q140045388 |
Radar intelligence
Patents
| EPO | 13 |
|---|
Publications (Crossref)
| Works | 6 |
|---|
Web history (Wayback)
| Domain | novaremed.com |
|---|
Wikidata
| QID | Q140045388 |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|